Snapshot from Aug 07, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Technology / Biogen diranersen tau-targeting...
Tech clinical trial results

Biogen diranersen tau-targeting Alzheimer's trial

Analysis based on 27 articles · First reported Jul 14, 2026 · Last updated Jul 14, 2026

Sentiment
40
Attention
6
Articles
27
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

Positive sentiment for Biogen and Ionis Pharmaceuticals as diranersen shows promise in a novel tau-targeting approach, potentially expanding the Alzheimer's treatment market. The results may reinvigorate investment in tau mechanisms, benefiting companies like Denali Therapeutics and NewAmsterdam Pharma.

Pharmaceuticals Biotechnology
Event Summary

Biogen presented Phase II trial results for diranersen, an antisense oligonucleotide targeting tau protein, at the Alzheimer s Association International Conference in London. The study of 416 participants with mild cognitive impairment or early Alzheimer's showed that the lowest dose (60 mg every 24 weeks) reduced cognitive decline by 26% compared to placebo, comparable to existing amyloid-targeting drugs. Diranersen lowered tau levels in cerebrospinal fluid by 50-65% but did not show a dose-response relationship. Side effects included injection site pain and temporary confusion, but no brain inflammation. Biogen plans a Phase III trial. Separately, UCSF opened the Alzheimer's Tau Platform to test multiple anti-tau therapies, and NewAmsterdam Pharma plans to study obicetrapib for Alzheimer's risk in APOE4 carriers.

Key Actions
80 Biogen announced results
40 NewAmsterdam Pharma planned study of obicetrapib
Entities Involved
stock
Biogen
Biogen's diranersen showed promising Phase II results, slowing cognitive decline by 26% in early Alzheimer's. The company plans a Phase III trial, positioning it as a leader in tau-targeting therapies.
Importance 100.0 Sentiment 60.0
stock
Ionis Pharmaceuticals
Ionis partnered with Biogen on diranersen, an antisense oligonucleotide. Positive trial results enhance Ionis's platform value and pipeline prospects.
Importance 80.0 Sentiment 55.0
per
Cath Mummery
Dr. Cath Mummery led the diranersen trial and presented the results at the conference.
Importance 50.0 Sentiment 0.0
ngo
Alzheimer s Association
The Alzheimer s Association hosted the conference where results were presented and commented on the significance of the findings.
Importance 40.0 Sentiment 0.0
govactor
United States — National Institutes of Health
NIH funded the Alzheimer's Tau Platform at UCSF, supporting research into anti-tau therapies.
Importance 30.0 Sentiment 0.0
stock
NewAmsterdam Pharma
NewAmsterdam plans to study obicetrapib for Alzheimer's risk in APOE4 carriers, potentially expanding its drug's indications.
Importance 30.0 Sentiment 30.0
cnt
United States
The United States has over 7 million Alzheimer's patients, highlighting the need for new treatments.
Importance 20.0 Sentiment 0.0
govactor
United States — Food and Drug Administration
FDA approval would be required for diranersen to reach the market, following potential Phase III success.
Importance 20.0 Sentiment 0.0
stock
Denali Therapeutics
Denali is developing transport vehicle technology to deliver Alzheimer's drugs across the blood-brain barrier, targeting tau and amyloid.
Importance 20.0 Sentiment 20.0
per
Adam Boxer
Dr. Adam Boxer of UCSF is involved in the Alzheimer's Tau Platform, testing anti-tau therapies.
Importance 20.0 Sentiment 0.0
priv
Banner Alzheimer s Institute
Jessica Langbaum of Banner commented on the promise of diranersen, but the institute was not directly involved.
Importance 10.0 Sentiment 0.0
per
Jessica Langbaum
Jessica Langbaum commented on the promise of diranersen but was not involved in the study.
Importance 10.0 Sentiment 0.0
per
Reisa Sperling
Dr. Reisa Sperling provided cautious optimism, noting the early stage of the research.
Importance 10.0 Sentiment 0.0
per
Ryan Watts
Ryan Watts, CEO of Denali Therapeutics, described the company's transport vehicle technology for brain drug delivery.
Importance 10.0 Sentiment 0.0
per
Robert Howard
Dr. Robert Howard commented on the small effect sizes and the need for clinically meaningful differences.
Importance 10.0 Sentiment 0.0
+ 1 more entities View on Dashboard
Relationships
Biogen related ↔ United States
Biogen related ↔ United States — Food and Drug Administration
Alzheimer s Association related ↔ United States — National Institutes of Health
Alzheimer s Association related ↔ United States
Alzheimer s Association related ↔ United States — Food and Drug Administration
United States — National Institutes of Health related ↔ United States
United States — National Institutes of Health related ↔ United States — Food and Drug Administration
United States related ↔ United States — Food and Drug Administration
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.